Biohaven Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BHVN | VIR | AAPG | LKFT | SLDB | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 1.78B | 1.91B | 1.43B | 1.94B | 719.48M | 3.48B |
| P/E (TTM) | — | — | — | 2.8 | — | — |
| Forward P/E | -6.3 | -4.5 | -20.0 | -24.9 | -3.9 | -9.0 |
| Price/book | 145.8 | 1.9 | 17.2 | 10.5 | 1.9 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −29.11% | +99.66% | −56.34% | −12.35% | +14.31% | +34.89% |
| Today | −2.24% | −3.42% | +3.80% | −0.54% | −2.33% | −0.14% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BHVN news ›Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
U.S.-listed drugmakers spent the week selling rights or buying products they can already sell. Cash went to approved pain drugs, a factory that makes imaging agents, and two license deals, including one that leaves the American company in…
Biohaven partners with Ono in $100m IgG degrader deal
The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan. Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with…
Biohaven signs licensing deal with Japanese drugmaker worth up to $100M
David joined Hartford Business Journal as senior staff writer in January 2024; his beats include health care, bioscience and the state legislature. A UConn graduate, his long career in journalism included serving as a reporter and/or…
Ono Pharmaceutical Secures Asian Rights to Biohaven's Autoimmune Drugs
www.marketscreener.com Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Secures Asian Rights to Biohaven's Autoimmune Drugs Published on 10/08/2026 at 10:55 pm EDT
Biohaven licenses IgG degrader portfolio to Japan’s Ono
Biohaven (BHVN) signs a deal with Ono Pharma (OPHLF) to outlicense its MoDE pan IgG degrader portfolio in several Asian countries. Read more here. Biohaven (BHVN) on Thursday announced an agreement with Ono Pharmaceutical (OPHLF) (OPHLY)…
Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia
Biohaven said Thursday it entered into an exclusive licensing deal with Ono Pharmaceutical to develop and commercialize its antibody degrader portfolio in Japan, South Korea, Taiwan, and Southeast... Biohaven Pharmaceutical Holding Company…
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven retains rights outside the licensed Asian markets and will receive approximately 20 percent royalties on Ono's territorial net sales. BHV-1300, an investigational small molecule that removes IgG antibodies, is in Phase 3…
Roche’s AI lab; Biohaven’s pivotal pause
Roche announced it’s building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven Pharma wants AI agents because they can do more than answer a question. They can choose tools, gather evidence and…
Biohaven reports 1,000-option grant at $12.34
Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies in immunology, obesity, neuroscience and oncology using multiple platforms. Biohaven reports 1,000-option grant at $12.34 Biohaven Ltd. disclosed…
Biohaven epilepsy drug hit by partial FDA hold
Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies in immunology, obesity, neuroscience and oncology using multiple platforms. Biohaven epilepsy drug hit by partial FDA hold FDA issues a partial…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com3
-
stocktitan.net2
-
hartfordbusiness.com1
-
macaubusiness.com1
-
newsable.asianetnews.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.